Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1615 1616 1617
This examiner grants 54% of resolved cases
Casey Shea Hagopian has handled 568 resolved cases in Art Unit 1611. Within Tech Center 1600, the examiner maintains an allowance rate of 54.4 percent. This rate suggests an examination environment where a portion of the applications reach issuance. The volume of cases indicates a set of practices for this examiner.
The median days to allowance is 1215, which is the timeline for patent prosecution. However, the interview lift of 33.3 percent is an indicator that verbal communication is effective. This lift suggests that an interview can improve the 54.4 percent base allowance rate. For practitioners, this means that while the process may take 1215 days, the use of interviews is a successful tactic for overcoming examiner objections. Strategic planning should include an interview to leverage this 33.3 percent boost and move the application toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17671071 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | Final Rejection | The Regents of the University of California |
| 18875229 | NAPROXEN SODIUM TABLETS PRODUCED USING A CONTINUOUS PROCESS | Non-Final OA | BAYER HEALTHCARE LLC |
| 19119944 | ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM | Non-Final OA | Solventum Intellectual Properties Company |
| 18870174 | ANTIMICROBIAL COMPOSITIONS AND ARTICLES MADE THEREFROM | Non-Final OA | Solventum Intellectual Properties Company |
| 18875297 | ORAL CARE COMPOSITION COMPRISING A PEROXIDE AND AN ETHYLENE OXIDE/PROPYLENE OXIDE BLOCK COPOLYMER | Non-Final OA | BASF SE |
| 18871415 | COSMETIC PRODUCT FOR TEMPORARILY SHAPING KERATIN-CONTAINING FIBERS | Non-Final OA | HENKEL AG & CO. KGAA |
| 18286541 | BIOCHEMICAL ACTIVATION OF DYSFUNCTIONAL SKELETAL STEM CELLS FOR SKELETAL REGENERATION | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18120726 | USE OF THERMOLYSIN TO REDUCE OR ELIMINATE BACTERIAL BIOFILMS FROM SURFACES | Final Rejection | SMITH & NEPHEW, INC. |
| 17767140 | COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES | Non-Final OA | The General Hospital Corporation |
| 18995446 | HYALURONIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | Non-Final OA | ASAHI KASEI KABUSHIKI KAISHA |
| 18860152 | Makeup Composition Comprising a Polyphenol, a Polyoxyalkylenated or Polyglycerolated Compound, a Monoalcohol and an Acid, and Method Employing Same | Non-Final OA | L'OREAL |
| 17691262 | Regenerative Tissue-Mimetic Multilayer Fused Microgel-Cell Construct | Final Rejection | University of South Carolina |
| 17753790 | HIGH LOAD FORMULATION CONTAINING A SULFOPOLYMER | Non-Final OA | Eastman Chemical Company |
| 18901643 | WOUND TREATMENT DEVICES, KITS, SYSTEMS, AND METHODS | Non-Final OA | Coloplast A/S |
| 18252849 | ELONGATED COMPOSITE FOR AN IMPLANT | Final Rejection | 206 Ortho, Inc. |
| 18563872 | SELECTIVELY PERMEABLE ANNULUS FIBERS AND METHODS OF USING SAME | Non-Final OA | ASPECT BIOSYSTEMS LTD. |
| 17863251 | METHODS AND DEVICES FOR NERVE REGENERATION | Non-Final OA | Tulavi Therapeutics, Inc. |
| 18278536 | Insecticidal Composition Comprising of Diamide, Moulting Hormone Agonist and Pyrethroid | Final Rejection | WILLOWOOD CHEMICALS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy